Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38396993)

  • 1. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
    Ezzati S; Salib S; Balasubramaniam M; Aboud O
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
    An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
    Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.
    Roth P; Weller M
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
    Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
    J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib in glioblastoma: lost in translation?
    Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME
    Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
    Westphal M; Maire CL; Lamszus K
    CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
    Kwatra MM
    Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.
    Liu F; Mischel PS
    Wiley Interdiscip Rev Syst Biol Med; 2018 Jan; 10(1):. PubMed ID: 28892308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
    Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
    Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
    Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
    J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
    Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.